Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5159 | 1.00 | ALDH1A1 (0.33) | ALDH1A1 | |
| SCHEMBL7283678 | 1.00 | ALDH1A1 (0.33) | ALDH1A1 | |
| SCHEMBL16145772 | 1.00 | ALDH1A1 (0.33) | ALDH1A1 | |
| SCHEMBL1476914 | 1.00 | ALDH1A1 (0.33) | ALDH1A1 | |
| SCHEMBL14720581 | 0.95 | — | — | |
| SCHEMBL10873496 | 0.85 | — | — | |
| SCHEMBL7815 | 0.77 | — | — | |
| SCHEMBL14740988 | 0.77 | — | — | |
| SCHEMBL9938216 | 0.73 | PNMT (0.34) | — | |
| SCHEMBL37649 | 0.72 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 105 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210121397-A1 | BIODEGRADABLE INTRAVITREAL TYROSINE KINASE IMPLANTS | ALLERGAN INC (US) | 2021-04-29 | — | — | US | claimed |
| US-10881608-B2 | Biodegradable intravitreal tyrosine kinase implants | ALLERGAN, INC. (US) | 2021-01-05 | — | — | US | claimed |
| EP-1742610-B1 | INTRAVITREAL IMPLANTS COMPRISING MICROSPHERES WHICH ENCAPSULATE A TYROSINE KINASE INHIBITOR AND A BIODEGRADABLE POLYMER | ALLERGAN INC (US) | 2013-06-12 | — | — | EP | claimed |
| EP-1902024-B1 | KINASE INHIBITORS | ALLERGAN INC (US) | 2013-04-17 | — | — | EP | claimed |
| EP-1750665-B1 | BIODEGRADABLE INTRAVITREAL TYROSINE KINASE INHIBITORS IMPLANTS | ALLERGAN INC (US) | 2012-07-11 | — | — | EP | claimed |
| US-8034957-B2 | Kinase inhibitors | ALLERGAN, INC. (US) | 2011-10-11 | — | — | US | claimed |
| US-7915443-B2 | Sulfoximines as kinase inhibitors | ALLERGAN, INC. (US) | 2011-03-29 | — | — | US | claimed |
| US-7749530-B2 | Kinase inhibitors | ALLERGAN, INC. (US) | 2010-07-06 | — | — | US | claimed |
| US-20100168199-A1 | Kinase Inhibitors | ALLENGAN, INC. (US) | 2010-07-01 | — | — | US | claimed |
| US-7692005-B2 | Kinase inhibitors | ALLERGAN, INC. (US) | 2010-04-06 | — | — | US | claimed |
| US-20070015748-A1 | Kinase Inhibitors | ALLERGAN, INC. | 2007-01-18 | — | — | US | claimed |
| WO-2007008895-A1 | KINASE INHIBITORS | ALLERGAN, INC. (US) | 2007-01-18 | — | — | WO | claimed |
| US-7015220-B2 | 3-(arylamino)methylene-1, 3-dihydro-2H-indol-2-ones as kinase inhibitors | ALLERGAN, INC. (US) | 2006-03-21 | — | — | US | claimed |
| US-20060025413-A1 | 3-(arylamino)methylene-1,3-dihydro-2H-indol-2-ones as kinase inhibitors | ALLERGAN, INC. | 2006-02-02 | — | — | US | claimed |
| US-20040198802-A1 | Kinase inhibitors for the treatment of disease | ALLERGAN, INC. | 2004-10-07 | — | — | US | claimed |
| US-20040198720-A1 | 3-(Arylamino)methylene-1, 3-dihydro-2H-indol-2-ones as kinase inhibitors | ANDREWS STEVEN W (US) | 2004-10-07 | — | — | US | claimed |
| US-6765012-B2 | FOR MODULATING TYROSINE KINASE SIGNAL TRANSDUCTION IN ORDER TO REGULATE, MODULATE AND/OR INHIBIT ABNORMAL CELL PROLIFERATION | ALLERGAN, INC. | 2004-07-20 | — | — | US | claimed |
| WO-2004050621-A2 | INDOL DERIVATIVES AND THEIR USE AS KINASE INHIBITORS | ALLERGAN, INC (US) | 2004-06-17 | — | — | WO | claimed |
| US-20040102509-A1 | KINASE INHIBITORS FOR THE TREATMENT OF DISEASE | ALLERGAN, INC. | 2004-05-27 | — | — | US | claimed |
| US-20030199478-A1 | 3-(Arylamino)methylene-1, 3-dihydro-2H-indol-2-ones as kinase inhibitors | ALLERGAN, INC. | 2003-10-23 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100168199-A1 | Kinase Inhibitors | ABL1, LCK, ERBB2 | ALDH1A1 2379/4885 |
| US-20030199478-A1 | 3-(Arylamino)methylene-1, 3-dihydro-2H-indol-2-ones as kinase inhibitors | ERBB2, MKI67, CDK2 | ALDH1A1 1651/4885 |
| US-20040198802-A1 | Kinase inhibitors for the treatment of disease | ABL1, ERBB2, LCK | ALDH1A1 2496/4885 |
| US-20210121397-A1 | BIODEGRADABLE INTRAVITREAL TYROSINE KINASE IMPLANTS | KDR, PTK2B, DSTYK | ALDH1A1 1500/4885 |
| US-20040102509-A1 | KINASE INHIBITORS FOR THE TREATMENT OF DISEASE | ABL1, ERBB2, LCK | ALDH1A1 2496/4885 |
| US-10881608-B2 | Biodegradable intravitreal tyrosine kinase implants | KDR, PTK2B, DSTYK | ALDH1A1 1500/4885 |
| US-20060025413-A1 | 3-(arylamino)methylene-1,3-dihydro-2H-indol-2-ones as kinase inhibitors | ERBB2, MKI67, CDK2 | ALDH1A1 1651/4885 |
| US-20070015748-A1 | Kinase Inhibitors | ABL1, LCK, ERBB2 | ALDH1A1 2379/4885 |
| US-20040198720-A1 | 3-(Arylamino)methylene-1, 3-dihydro-2H-indol-2-ones as kinase inhibitors | ERBB2, MKI67, CDK2 | ALDH1A1 1651/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.